Universe Pharmaceuticals (UPC) Stock Price, News & Analysis

Company Overview

Universe Pharmaceuticals, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action. In parallel, Universe is exploring additional pipeline assets aimed at reducing post-operative scarring and controlling inflammation in anterior segment surgeries. Preclinical studies have demonstrated favorable pharmacokinetics and tissue penetration in animal models, supporting the potential for once-daily dosing regimens.

Headquartered in the United Kingdom with a research subsidiary in the United States, Universe Pharmaceuticals maintains collaborations with academic institutions and contract development organizations to accelerate its drug development programs. The company is led by a management team with extensive experience in ophthalmology drug development and regulatory strategy, positioning it to advance its candidates through late-stage clinical trials and toward commercialization.

Key Stats

• Today's Range: $2.80 to $3.07
• 50-Day Range: $2.21 to $3.30
• 52-Week Range: $2.00 to $11.00
• Volume: 11,787 shs
• Average Volume: 13,496 shs
• Market Capitalization: $1.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Universe Pharmaceuticals Stock Analysis - MarketRank™

Universe Pharmaceuticals scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Universe Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Universe Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Universe Pharmaceuticals has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UPC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Universe Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Universe Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Universe Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

1 people have searched for UPC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Universe Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

57.38% of the stock of Universe Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.18% of the stock of Universe Pharmaceuticals is held by institutions.

UPC Stock Analysis - Frequently Asked Questions

How have UPC shares performed this year?

Universe Pharmaceuticals' stock was trading at $3.81 at the start of the year. Since then, UPC shares have decreased by 24.0% and is now trading at $2.8950.

How were Universe Pharmaceuticals' earnings last quarter?

Universe Pharmaceuticals INC (NASDAQ:UPC) announced its quarterly earnings results on Thursday, January, 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The company earned $8.92 billion during the quarter.

When did Universe Pharmaceuticals' stock split?

Universe Pharmaceuticals's stock reverse split on the morning of Wednesday, November 13th 2024.The 1-15 reverse split was announced on Wednesday, November 13th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Universe Pharmaceuticals IPO?

Universe Pharmaceuticals (UPC) raised $30 million in an IPO on Tuesday, March 23rd 2021. The company issued 5,000,000 shares at $5.00-$7.00 per share. Univest Securities, LLC served as the underwriter for the IPO.

How do I buy shares of Universe Pharmaceuticals?

Shares of UPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 1/29/2026
• Today: 5/06/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPC
• Previous Symbol: NYSE:UPC
• CIK: 1809616
• Web: N/A
• Phone: 86-0796-8403309
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 3.90

Sales & Book Value

• Annual Sales: $17.86 million
• Price / Sales: 0.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $99.64 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 560,000
• Free Float: 240,000
• Market Cap: $1.62 million
• Optionable: N/A
• Beta: 1.58